MedPath

Early Speaking Valve in Ventilator Weaning: Effects on Communication, Depression, and Quality of Life

Not Applicable
Not yet recruiting
Conditions
Respiratory Failure
Communication Disorders
Depression
Quality of Life
Registration Number
NCT07005596
Lead Sponsor
Far Eastern Memorial Hospital
Brief Summary

This study evaluates the impact of early tracheostomy speaking valve intervention on communication ability, depression levels, and quality of life in ventilator-dependent patients during the weaning phase. Participants will be randomly assigned to either an experimental group using the Passy-Muir speaking valve or a control group employing standard non-verbal communication methods. Structured questionnaires will be used at multiple time points to assess changes in patient outcomes. The study aims to provide evidence supporting the use of speaking valves to enhance communication and emotional well-being in tracheostomy patients, potentially improving recovery and care strategies.

Detailed Description

This randomized controlled trial investigates the effects of early intervention using the Passy-Muir speaking valve on communication, depression, and quality of life in tracheostomy patients undergoing ventilator weaning. The study will enroll 70 participants from the respiratory care center at Far Eastern Memorial Hospital, randomly assigned to either the experimental group (speaking valve intervention) or the control group (standard non-verbal communication methods). Data will be collected using validated assessment tools at baseline, week 1, week 2, and week 4. The primary outcomes include improvements in patient communication, reduction in depressive symptoms, and enhancement of overall quality of life. Statistical analysis will be conducted using SPSS 22.0, employing t-tests, chi-square tests, and generalized estimating equations (GEE). Ethical considerations include informed consent, patient confidentiality, and adherence to IRB-approved protocols. Findings from this study will contribute to evidence-based practices for tracheostomy patient care and guide clinical decision-making on communication strategies during ventilator weaning.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Age: ≥18 years old
  • Consciousness: Glasgow Coma Scale (GCS) score 13-15 (can voluntarily open eyes or respond when called, able to follow instructions to move)
  • Tracheostomy: Performed ≥24 hours, with no bleeding, pain, subcutaneous emphysema, pneumothorax, or infection
  • Ventilator Weaning: Trained according to the hospital's Respiratory Care Center standards, able to undergo spontaneous breathing training during the day
  • Ventilator Settings: FiO2 ≤40%
  • Vital Signs: Stable:
  • Heart rate 60-100 beats/min
  • Respiratory rate 12-20 breaths/min
  • Systolic blood pressure <150 mmHg, diastolic blood pressure <90 mmHg
  • Blood oxygen saturation 95-100%, no dyspnea complaints
  • Richmond Agitation-Sedation Scale (RASS) between -1 and +1
  • Language: Able to communicate in Mandarin, Taiwanese, or Hakka
  • Consent: Willing to participate in the study
Exclusion Criteria
  • Recent surgery, anesthesia, or sedative use affecting consciousness
  • Severe unstable vital signs or inability to breathe normally
  • Upper airway obstruction or vocal cord paralysis
  • High dependence on ventilators or high-concentration oxygen therapy
  • History of depression or currently taking antidepressant medication

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Communication Ability (Measured using the Communication Difficulty Scale)From enrollment to 4 weeks post-enrollment

Communication ability will be assessed using the Communication Difficulty Scale (CDS), a validated instrument comprising 13 items designed to measure speech effectiveness in tracheostomy patients. Each item is rated on a 5-point Likert scale (0-4 per item, total score range: 0-52 points), where higher scores indicate greater communication difficulty. Assessments will be conducted at baseline (T0), week 1 (T1), week 2 (T2), and week 4 (T3).

Statistical analysis will evaluate changes in communication ability over time using generalized estimating equations (GEE), accounting for intra-subject variability and adjusting for potential confounders such as age, underlying respiratory condition, and baseline cognitive function.

Depression (Measured using the Patient Health Questionnaire-9, PHQ-9)From enrollment to 4 weeks post-enrollment

Depression symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9), a validated screening tool widely used in clinical and research settings. The PHQ-9 consists of 9 items, each rated on a 4-point Likert scale (0-3 per item, total score range: 0-27 points), where higher scores indicate greater depressive symptoms. Assessments will be conducted at baseline (T0), week 1 (T1), week 2 (T2), and week 4 (T3).

Statistical analysis will evaluate changes in depression scores over time using generalized estimating equations (GEE), adjusting for potential confounders such as age, baseline respiratory function, and pre-existing mental health conditions.

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.